New analysis from the EARLY TAVR trial showed patients between the age of 65 and 70 years old derived the most benefits of a strategy of early intervention with transcatheter aortic valve replacement ...

Not surprisingly, older patients fared worse, but some older and younger patients saw stroke benefits requiring more study.

Edwards’ SAPIEN 3 platform becomes the first TAVR system approved by the FDA for asymptomatic severe aortic stenosis patients ...

Edwards Lifesciences announced the FDA approved its transcatheter aortic valve replacement platform for treatment of severe ...

FDA approved the Sapien 3 transcatheter aortic valve replacement (TAVR) platform for treatment of severe aortic stenosis ...

The agency’s decision for the balloon-expandable Sapien 3 platform is based on groundbreaking results from EARLY TAVR.

Describes the nature of a clinical study. Types include: Observational study — observes people and measures outcomes without affecting results. Interventional study (clinical trial) — studies new ...

Please provide your email address to receive an email when new articles are posted on . Electronic provider notification led to more aortic valve replacement procedures after a diagnosis of severe ...

Aortic stenosis is the most common valvular lesion in patients above the age of 65. The etiology, presentation, and management of aortic stenosis differs in the elderly compared to younger ...

Blood enters the left ventricle through the mitral valve and leaves through the aortic valve. A stenotic valve is a valve opening that has gotten smaller and is partially obstructing blood flow. In ...

The timing of aortic valve replacement (AVR) in asymptomatic patients with severe aortic stenosis has been debated for several decades. Based on observational data and expert opinion, international ...